At a glance
ClinicalIndex Comparison RecordPhase 2Not Yet Recruiting· 430 target
Drug / intervention
JSKN033drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Antitumor Activity of JSKN033 in Chinese Subjects with Advanced Malignant Tumors
Jiangsu Alphamab Biopharmaceuticals Co., Ltd·interventional·Posted Jan 13, 2025·Updated Jan 13, 2025
In Brief
A Phase 2 clinical trial evaluating JSKN033 for Advanced Malignant Tumors. Not yet recruiting, targeting 430 participants.
Detailed Summary
This is a phase I/II multicenter study to evaluate the safety and efficacy of JSKN033 in Chinese subjects with unresectable locally advanced/metastatic solid tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Malignant Tumors
Countries--
Collaborators--
Timeline
Phase 2Not Yet Recruiting
2025202620272028
First PostedJan 2025
Enrollment StartJan 2025
TodayJul 2026
Primary CompletionDec 2026
Study CompletionDec 2027
First PostedJan 13, 2025
Enrollment StartJan 15, 2025
Primary CompletionDec 31, 2026
Study CompletionDec 31, 2027
TodayJul 1, 2026
Enrollment to primary: 2.0 yearsPosted 1.5 years agoPrimary completion in 6 months
Interventions
JSKN033drug
JSKN033 should be administered subcutaneously on the first day of each week cycle/ each 2-week cycle